TWO SIGMA ADVISERS, LP - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 199 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.

Quarter-by-quarter ownership
TWO SIGMA ADVISERS, LP ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$16,771,897
+11.5%
2,368,912
+10.8%
0.04%
+13.2%
Q2 2023$15,048,788
-18.1%
2,137,612
-3.0%
0.04%
-19.1%
Q1 2023$18,370,618
-18.8%
2,202,712
+11.8%
0.05%
-25.4%
Q4 2022$22,626,070
-10.9%
1,970,912
-2.2%
0.06%
-14.9%
Q3 2022$25,399,000
+15.2%
2,015,812
-3.2%
0.07%
+17.5%
Q2 2022$22,042,000
-23.5%
2,083,412
+17.6%
0.06%
-18.2%
Q1 2022$28,797,000
-3.4%
1,771,012
-17.7%
0.08%
+2.7%
Q4 2021$29,804,000
+8.0%
2,151,912
+12.0%
0.08%
+4.2%
Q3 2021$27,605,000
+146.6%
1,921,012
+171.3%
0.07%
+140.0%
Q2 2021$11,195,000
+391.0%
708,112
+215.8%
0.03%
+400.0%
Q1 2021$2,280,000
-76.6%
224,212
-82.9%
0.01%
-76.9%
Q4 2020$9,757,000
+50.3%
1,309,712
-30.7%
0.03%
+36.8%
Q3 2020$6,490,000
-35.7%
1,889,312
-10.8%
0.02%
-36.7%
Q2 2020$10,096,000
+215.5%
2,118,812
+32.4%
0.03%
+150.0%
Q1 2020$3,200,000
-38.2%
1,599,912
+6.5%
0.01%0.0%
Q4 2019$5,181,000
+106.7%
1,501,812
+71.7%
0.01%
+100.0%
Q3 2019$2,507,000
+50.5%
874,912
+99.0%
0.01%
+50.0%
Q2 2019$1,666,000
+5.6%
439,612
+126.8%
0.00%0.0%
Q1 2019$1,578,000
+18.2%
193,812
+17.2%
0.00%0.0%
Q4 2018$1,335,000
-11.7%
165,412
-16.5%
0.00%0.0%
Q3 2018$1,512,000
+55.9%
198,212
+17.1%
0.00%
+33.3%
Q2 2018$970,000
+117.0%
169,212
+80.4%
0.00%
+200.0%
Q1 2018$447,000
-3.7%
93,800
-0.6%
0.00%0.0%
Q4 2017$464,000
+3.6%
94,400
+10.4%
0.00%0.0%
Q3 2017$448,000
+26.9%
85,500
+34.6%
0.00%0.0%
Q2 2017$353,000
+38.4%
63,512
+108.8%
0.00%0.0%
Q1 2017$255,000
+13.8%
30,412
+32.7%
0.00%
-50.0%
Q3 2014$224,000
-70.5%
22,912
-61.6%
0.00%
-66.7%
Q2 2014$760,00059,6120.01%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q3 2021
NameSharesValueWeighting ↓
Burrage Capital Management LLC 1,105,673$8,237,0006.28%
Sarissa Capital Management LP 8,175,000$60,903,0006.22%
ORACLE INVESTMENT MANAGEMENT INC 2,980,870$22,207,0002.78%
DG Capital Management, LLC 1,075,732$8,014,0001.70%
Ghost Tree Capital, LLC 900,000$6,705,0001.49%
Parkman Healthcare Partners LLC 538,370$4,011,0001.03%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 5,835,810$43,477,0000.86%
Formidable Asset Management, LLC 470,419$3,470,0000.80%
KNOTT DAVID M 219,461$1,635,0000.74%
Altium Capital Management LP 250,000$1,863,0000.70%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders